Your browser doesn't support javascript.
loading
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).
Ramalingam, S; Goss, G; Rosell, R; Schmid-Bindert, G; Zaric, B; Andric, Z; Bondarenko, I; Komov, D; Ceric, T; Khuri, F; Samarzija, M; Felip, E; Ciuleanu, T; Hirsh, V; Wehler, T; Spicer, J; Salgia, R; Shapiro, G; Sheldon, E; Teofilovici, F; Vukovic, V; Fennell, D.
Afiliação
  • Ramalingam S; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, USA ssramal@emory.edu.
  • Goss G; Division of Medical Oncology, University of Ottawa, Ottawa, Canada.
  • Rosell R; Medical Oncology Service, Catalan Institute of Oncology, Badalona, Spain.
  • Schmid-Bindert G; Department of Surgery, University Medical Center Mannheim, Mannheim, Germany.
  • Zaric B; Institute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Novi Sad.
  • Andric Z; Clinic for Oncology, Medical Center Bezanijska Kosa, Belgrade, Serbia.
  • Bondarenko I; Department of Oncology, Multiple-Discipline Clinical Hospital #4, Dnipropetrovsk, Ukraine.
  • Komov D; Surgical Department of Tumor Diagnostics, Russian Academy of Medical Science, Moscow, Russia.
  • Ceric T; Oncology Clinic, University of Sarajevo Clinics Center, Sarajevo, Bosnia.
  • Khuri F; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, USA.
  • Samarzija M; Department for Respiratory Diseases Jordanovac, University of Zagreb, Zagreb, Croatia.
  • Felip E; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Ciuleanu T; Department of Medical Oncology, Oncological Institute Ion Chiricuta, Cluj-Napoca, Romania.
  • Hirsh V; Department of Medical Oncology, McGill University Health Centre, Montreal, Canada.
  • Wehler T; Third Department of Internal Medicine, Johannes Gutenberg-University of Mainz, Mainz, Germany.
  • Spicer J; Department of Research Oncology, King's College London, London, UK.
  • Salgia R; Department of Medicine, University of Chicago, Chicago.
  • Shapiro G; Department of Medical Oncology, Dana Farber Cancer Institute, Boston.
  • Sheldon E; Department of Clinical Research, Synta Pharmaceuticals Corp., Lexington, USA.
  • Teofilovici F; Department of Clinical Research, Synta Pharmaceuticals Corp., Lexington, USA.
  • Vukovic V; Department of Clinical Research, Synta Pharmaceuticals Corp., Lexington, USA.
  • Fennell D; Department of Cancer Studies, University of Leicester, Leicester, UK.
Ann Oncol ; 26(8): 1741-8, 2015 Aug.
Article em En | MEDLINE | ID: mdl-25997818
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Estados Unidos